Abstract
PurposeTo evaluate the science and technology (S&T) development framework within Estonia, a small transition country, and its biotechnology sector.Design/methodology/approachIn the general overview the main concepts, actors and environment of S&T system in the triple helix context are analyzed. The empirical study explores the general research and development (R&D) environment of Estonia and particularly the biotechnology sector by mapping the actors, strategy of companies (all small and medium‐sized enterprises – SMEs), innovation processes and related expenditures of the public sector and private businesses.FindingsThe study results indicate the ratio of basic and applied research, and product/service development in the gross R&D funding structure in Estonia to be 3:3:4; in the biotechnology sector this ratio is 11:5:1. The structure of research expenditure in the public sector mostly reflects the success of Estonian biosciences rather than the success of biotech as a business sector.Practical implicationsWays for improving the S&T system are suggested.Originality/valueMapping the actors, and measurement of the structure of the R&D expenses in the Estonian biotech sector and in SMEs in particular.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
